Kymera Therapeutics, Inc.
KYMR•NASDAQ•Healthcare•Biotechnology

About Kymera Therapeutics

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis. The company also develops STAT6, a type 2 inflammation in allergic and atopic diseases; and TYK2 to treat autoimmune and inflammatory diseases. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside of the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Company Information

SectorHealthcare
IndustryBiotechnology
CEONello Mainolfi
Founded2015
IPO DateAugust 21, 2020
Employees188
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock
SubtypeCommon Stock

Contact Information

Websitewww.kymeratx.com
Phone857 285 5300
Address
500 North Beacon Street, 4th Floor Watertown, Massachusetts 02472 United States

Corporate Identifiers

CIK0001815442
CUSIP501575104
ISINUS5015751044
EIN81-2992166
SIC2836

Leadership Team & Key Executives

Dr. Nello Mainolfi M.D., Ph.D.
Co-Founder, President, Chief Executive Officer and Director
Dr. Bruce L. Booth DPHIL, Ph.D.
Co-Founder and Independent Chairman
Bruce N. Jacobs CFA
Chief Financial Officer
Dr. Jeremy G. Chadwick Ph.D.
Chief Operating Officer
Dr. Jared A. Gollob M.D.
Chief Medical Officer
Justine E. Koenigsberg
Vice President of Investor Relations
Brian R. Adams J.D.
Chief Legal Officer and Corporate Secretary
Karen Weisbach
Head of People and Culture
Dr. Juliet Williams B.A Ph.D.
Head of Research
Noah Goodman M.B.A.
Chief Business Officer